KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBIT Margin: 2018-2025

Historic EBIT Margin for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -8.19%.

  • Castle Biosciences' EBIT Margin fell 1411.00% to -8.19% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.17%, marking a year-over-year decrease of 984.00%. This contributed to the annual value of 2.61% for FY2024, which is 3354.00% up from last year.
  • Latest data reveals that Castle Biosciences reported EBIT Margin of -8.19% as of Q3 2025, which was down 66.12% from -4.93% recorded in Q2 2025.
  • Castle Biosciences' 5-year EBIT Margin high stood at 5.92% for Q3 2024, and its period low was -91.30% during Q1 2022.
  • In the last 3 years, Castle Biosciences' EBIT Margin had a median value of -8.19% in 2025 and averaged -16.13%.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by 7,252bps in 2022, then skyrocketed by 6,749bps in 2024.
  • Over the past 5 years, Castle Biosciences' EBIT Margin (Quarterly) stood at -60.59% in 2021, then surged by 103bps to -59.55% in 2022, then surged by 5,100bps to -8.56% in 2023, then spiked by 1,325bps to 4.69% in 2024, then slumped by 1,411bps to -8.19% in 2025.
  • Its EBIT Margin was -8.19% in Q3 2025, compared to -4.93% in Q2 2025 and -31.74% in Q1 2025.